BRAF and neoplasm: Because of the genetic heterogeneity commonly observed in tumor samples, it is unclear if these secondary mutations were already present in some sub-populations of BRAF V600E tumor cells, or if BRAF inhibitor treatment itself drives the accumulation of additional mutations.